Iqvia Holdings Inc. splits its revenue into 3 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Research And Development Solutions at $8.9 billion, 55% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
17,311
|
16,310
|
15,405
|
14,984
|
14,410
|
13,874
|
11,359
|
11,088
|
10,412
|
9,739
|
6,878
|
| Research And Development Solutions |
—
|
8,896
+4.3%
share 54.5%
|
8,527
+1.6%
share 55.4%
|
8,395
+6.0%
share 56.0%
|
7,921
+4.8%
share 55.0%
|
7,556
+31.2%
share 54.5%
|
5,760
-0.5%
share 50.7%
|
5,788
+5.9%
share 52.2%
|
5,465
+7.1%
share 52.5%
|
5,105
share 52.4%
|
—
|
| Technology And Analytics Solutions |
—
|
6,626
+7.6%
share 40.6%
|
6,160
+5.1%
share 40.0%
|
5,862
+2.0%
share 39.1%
|
5,746
+3.8%
share 39.9%
|
5,534
+13.9%
share 39.9%
|
4,858
+8.3%
share 42.8%
|
4,486
+8.4%
share 40.5%
|
4,137
+12.4%
share 39.7%
|
3,682
share 37.8%
|
—
|
| Contract Sales And Medical Solutions |
—
|
788
+9.7%
share 4.8%
|
718
-1.2%
share 4.7%
|
727
-2.2%
share 4.9%
|
743
-5.2%
share 5.2%
|
784
+5.8%
share 5.7%
|
741
-9.0%
share 6.5%
|
814
+0.5%
share 7.3%
|
810
-11.5%
share 7.8%
|
915
share 9.4%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- IQV (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Durham, NC
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1478242
- Former names
- Quintiles IMS Holdings, Inc. (until Nov 3, 2017); Quintiles Transnational Holdings Inc. (until Sep 22, 2016)
Other Services-Commercial Physical & Biological Research companies
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.